

Attorney Docket No.: 4814.214-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Charlotte Johansen Confirmation No: 5761

Serial No.: 09/815,848

Group Art Unit: 1652

Filed: March 23, 2001

Examiner: R. Prouty

For: Antimicrobia1 Peroxidase Compositions

FAX RECEIVED

APR 25 2003

GROUP 1600

CERTIFICATE OF FACSIMILE TRANSMISSION

Commissioner for Patents
Washington, DC 20231

OFFICIAL


Sir:

I hereby certify that the attached correspondence comprising:

1. Response to Restriction Requirement


was sent to the United States Patent and Trademark Office by telefax to the attention of Examiner R. Prouty, fax number (703) 308-4242.

Respectfully submitted,



Lourdes Ayala
Novozymes North America, Inc.
500 Fifth Avenue, Suite 1600
New York, NY 10110
(212) 840-0097

Date: April 24, 2003



Attorney Docket No.: 4814.214-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Charlotte Johansen Confirmation No: 5761

Serial No.: 09/815,848 Group Art Unit: 1652

Filed: March 23, 2001 Examiner: R. Prouty

For: Antimicrobia1 Peroxidase Compositions

RESPONSE TO RESTRICTION REQUIREMENT

Commissioner for Patents
Washington, DC 20231

Sir:

This paper is filed in response to the Office Action mailed March 25, 2003 that made a restriction requirement between the following groups:

Group I – claims 1-22 and 27-30 drawn to methods of killing or inhibiting a microorganism,

Group II – claims 23-25 drawn to methods of preserving a cosmetic product, and

Group III – claim 26 drawn to methods of cleaning contact lenses.

In addition, Applicants were requested to elect a species of enhancing agent and environment in which the microorganism is present.


In response, Applicants elect with traverse the invention of Group I, and syringate derivatives as the species of enhancing agent and laundry as the species of environment. Claims 1-6, 10, 11, 15, 17, 18, 20 and 22 read thereon. Applicants hereby reserve the right to file continuing applications directed to the nonelected subject matter.

The basis for traverse is that there would not be a serious burden on the examiner if restriction and election of species were not required.

The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this response or application.

Respectfully submitted,

Date: April 24, 2003


Elias J. Lambiris, Reg. No. 33,728
Novozymes North America, Inc.
500 Fifth Avenue, Suit 1600
New York, NY 10110
(212) 840-0097